S
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Steve Lee's research focuses on cancer, particularly head and neck cancers, and the underlying molecular mechanisms. He has investigated phenotypic features, biology, and potential therapeutic targets in thyroid carcinoma. His work also includes developing predictive scores for survival in oral squamous cell carcinoma, such as the REASON score, which incorporates epigenetic and clinicopathologic factors. Lee has explored the role of neurotrophin pathway receptors in perineural invasion, metastasis, and pain associated with oral cancer. His research also extends to noninvasive methods for epigenomic profiling, using brush swabs as a surrogate for tissue biopsies, and applying artificial intelligence to analyze epigenomic, transcriptomic, and histologic signatures of tobacco use in oral squamous cell carcinoma.
In addition to cancer research, Lee has contributed to studies in otolaryngology, evaluating the diagnostic and management applications of artificial intelligence tools like ChatGPT in clinical scenarios. His work has also involved analyzing different surgical techniques for scapholunate reconstruction in cases of dorsal intercalated segment instability. Furthermore, Lee has been involved in molecular monitoring of Equine herpesvirus-1 (EHV-1) in performance horses through nasal and environmental sample testing.
With a high-impact researcher designation, Lee has accumulated 192 publications and 4,978 citations, with an h-index of 35. He leads a research group and has collaborated with Shiv Srivastava at the University of Arkansas for Medical Sciences on three shared publications. His recent activity indicates ongoing engagement in research.
Metrics
- h-index: 35
- Publications: 190
- Citations: 4,976
Selected Publications
-
479MO Erlotinib plus bevacizumab in patients with metastatic solid tumors with EGFR amplification: Results from the KOSMOS-II (KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced solid tumors, KCSG AL 22-09) (2024)
-
PER- AND POLYFLUOROALKYL SUBSTANCES: AN ATYPICAL RISK FACTOR IN CAD (2024)
-
Tumor Cell Stemness and Stromal Cell Features Contribute to Oral Cancer Outcome Disparity in Black Americans (2024)
-
Number of sinus procedures reduces inpatient mortality for invasive fungal rhinosinusitis (2024)
-
Patient Satisfaction with Nonopioid Postoperative Analgesia in Head and Neck Surgery: A Prospective Randomized Trial (2024)
-
Artificial intelligence-based epigenomic, transcriptomic and histologic signatures of tobacco use in oral squamous cell carcinoma (2024)
-
Abstract 3772: Tissue-niche-based and cell-type-selective in-depth proteomics (2024)
-
Data from Evaluation of the 8q24 Prostate Cancer Risk Locus and <i>MYC</i> Expression (2023)
-
PB1309 Switching from Factor VIIa to Emicizumab in Patients with Hemophilia A and Inhibitor (HAI) in Korea (2023)
-
Intraneural ganglion cyst of the peroneal nerve at the lateral knee: A case report and literature review (2023)
-
Diagnostic and Management Applications of ChatGPT in Structured Otolaryngology Clinical Scenarios (2023)
-
PO-1174 Clinical outcomes of ipsilateral versus bilateral neck irradiation for unilateral tonsillar cancer (2023)
-
Transoral Laser Resection of the Tongue Base in the Workup of Unknown Primary Head and Neck Squamous Cell Carcinoma (2023)
-
Supplementary Figure 1 from Evaluation of the 8q24 Prostate Cancer Risk Locus and <i>MYC</i> Expression (2023)
-
Data from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients (2023)
Collaboration Network
Top Collaborators
Pedro A. Andrade Filho
Loma Linda University Medical Center (US)
18 shared publications
- Targeting Tumor Microenvironment Akt Signaling Represents a Potential Therapeutic Strategy for Aggressive Thyroid Cancer
- Tumor Cell Stemness and Stromal Cell Features Contribute to Oral Cancer Outcome Disparity in Black Americans
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 18 shared publications
Christopher A. Lord
16 shared publications
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 1 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 16 shared publications
Hyun-Bae Jie
16 shared publications
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 1 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 16 shared publications
H. Carter Davidson
16 shared publications
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 1 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 16 shared publications
Andrés López‐Albaitero
16 shared publications
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 1 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 16 shared publications
Sandra P. Gibson
16 shared publications
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 1 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 16 shared publications
William E. Gooding
16 shared publications
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 1 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 16 shared publications
Soldano Ferrone
16 shared publications
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 1 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 16 shared publications
Robert L. Ferris
16 shared publications
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 1 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 16 shared publications
Raghvendra M. Srivastava
12 shared publications
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 5 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 12 shared publications
Paul C. Walker
Loma Linda University Health Care (US)
8 shared publications
- The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma
- Neurotrophin Pathway Receptors NGFR and TrkA Control Perineural Invasion, Metastasis, and Pain in Oral Cancer
- Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer
- Artificial intelligence-based epigenomic, transcriptomic and histologic signatures of tobacco use in oral squamous cell carcinoma
- Dysphagia Severity and Outcomes Following Iatrogenic High Vagal Nerve Injury
Showing 5 of 8 shared publications
Chi T. Viet
Loma Linda University (US)
7 shared publications
- The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma
- Neurotrophin Pathway Receptors NGFR and TrkA Control Perineural Invasion, Metastasis, and Pain in Oral Cancer
- Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer
- Artificial intelligence-based epigenomic, transcriptomic and histologic signatures of tobacco use in oral squamous cell carcinoma
- Brush Swab As A Noninvasive Surrogate for Tissue Biopsies in Oral Cancer Patients To Develop Clinically Translatable Epigenetic Biomarkers
Showing 5 of 7 shared publications
Gary Yu
New York University (US)
7 shared publications
- The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma
- Neurotrophin Pathway Receptors NGFR and TrkA Control Perineural Invasion, Metastasis, and Pain in Oral Cancer
- Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer
- Artificial intelligence-based epigenomic, transcriptomic and histologic signatures of tobacco use in oral squamous cell carcinoma
- Brush Swab As A Noninvasive Surrogate for Tissue Biopsies in Oral Cancer Patients To Develop Clinically Translatable Epigenetic Biomarkers
Showing 5 of 7 shared publications
Kesava Asam
New York University (US)
7 shared publications
- The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma
- Neurotrophin Pathway Receptors NGFR and TrkA Control Perineural Invasion, Metastasis, and Pain in Oral Cancer
- Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer
- Artificial intelligence-based epigenomic, transcriptomic and histologic signatures of tobacco use in oral squamous cell carcinoma
- Brush Swab As A Noninvasive Surrogate for Tissue Biopsies in Oral Cancer Patients To Develop Clinically Translatable Epigenetic Biomarkers
Showing 5 of 7 shared publications
Carissa M. Thomas
University of Alabama at Birmingham (US)
7 shared publications
- The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma
- Neurotrophin Pathway Receptors NGFR and TrkA Control Perineural Invasion, Metastasis, and Pain in Oral Cancer
- Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer
- Artificial intelligence-based epigenomic, transcriptomic and histologic signatures of tobacco use in oral squamous cell carcinoma
- Brush Swab As A Noninvasive Surrogate for Tissue Biopsies in Oral Cancer Patients To Develop Clinically Translatable Epigenetic Biomarkers
Showing 5 of 7 shared publications
Similar Researchers
Based on overlapping research topics
Fraley, Patrick
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer-related molecular mechanisms research
Epigenetics and DNA Methylation
Heba Allam
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer-related molecular mechanisms research
Molecular Biology Techniques and Applications
Guo-Lei Zhou
Arkansas State University
Cancer-related molecular mechanisms research
Epigenetics and DNA Methylation
Molecular Biology Techniques and Applications
Nathan Avaritt
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Molecular Biology Techniques and Applications
Viral Infections and Vectors
Aaron J. Storey
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Epigenetics and DNA Methylation
Molecular Biology Techniques and Applications
Jahangir Alam
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Epigenetics and DNA Methylation
Molecular Biology Techniques and Applications